Immuno- and genetic therapy in autoimmune diseases

Genes and Immunity

Volumn 1, Issue 5, 2000, Pages 295-307

  Chernajovsky, Yuti ^a   Dreja, H ^a   Daly, G ^a   Annenkov, A ^a   Gould, D ^a   Adams, G ^a   Croxford, J L ^b   Baker, D ^b   Podhajcer, O L ^c   Mageed, R A ^d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Diabetes; Gene therapy; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

ALLERGIC ENCEPHALOMYELITIS; ANIMAL; AUTOIMMUNE DISEASE; DISEASE MODEL; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; MOUSE MUTANT; MULTIPLE SCLEROSIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSGENIC MOUSE;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE THERAPY; HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MULTIPLE SCLEROSIS;

EID: 0034209206     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6363683     Document Type: Review

References (211)

1. McDevitt HO. The role of MHC class II molecules in susceptibility and resistance to autoimmunity. Curr Opinion In Immunol 1998; 10: 677-681.
2. Chao CC, Sytwu HK, Chen E, Toma J, McDevitt HO. The role of MHC class II molecules in susceptibility to type I diabetes: Identification of peptide epitopes and characterization of the T cell repertoire. Proc Natl Acad Sci USA 1999; 96: 9299-9304.
3. Rabinovich GA, Daly G, Dreja H et al. Recombinant Galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med 1999; 190: 385-397.
4. Ebers GC, Kukay K, Bulman DE et al. A full genome search in multiple sclerosis. Nat Genet 1996; 13: 472-476.
5. Ebers GC, Dyment DA. Genetics of multiple sclerosis. Sem Neurol 1998; 18: 295-299.
6. Sawcer S, Goodfellow PN. Inheritance of susceptibility to multiple sclerosis. Curr Op Immunol 1998; 10: 697-703.
7. Vandenbark AA, Chou YK, Whitham R et al. Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial. Nat Med 1996; 2: 1109-1115.
8. Rudick RA, Ransohoff RM, Lee J-C et al. In vivo effects of interferon beta-1a on immunosuppresive cytokines in multiple sclerosis. Neurology 1998; 50: 1294-1300.
9. Croxford JL, O'Neill JK, Baker D. Polygenic control of experimental allergic encephalomyelitis in Biozzi ABH and BALB/c mice. J Neuroimmunol 1997; 74: 205-211.
10. Maron R, Hancock WW, Slavin A et al. Genetic susceptibility or resistance to autoimmune encephalomyelitis in MHC congenic mice is associated with differential production of pro-and anti-inflammatory cytokines. Intl Immunol 1999; 11: 1573-1580.
11. Holmdahl R. Genetics of susceptibility to chronic experimental encephalomyelitis and arthritis. Curr Op Immunol 1998; 10: 710-717.
12. Miller SD, Vanderlugt CL, Smith Begolka W et al. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med 1997; 3: 1133-1136.
13. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695-705.
14. Tuohy VK, Fritz RB, Ben-Nun A. Self-determinants in autoimmune demyelinating disease: Changes in T-cell response specificity. Curr Opin Immunol 1994; 6: 887-891.
15. Khoury SJ, Akalin E, Chandraker A et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995; 155: 4521-4524.
16. Offner H, Celnik B, Bringman TS et al. Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis. J Neuroimmunol 1990; 28: 177-184.
17. Baker D, Butler D, Scallon BJ et al. Control of established EAE by inhibition of TNF activity within the CNS using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994; 24: 2040-2048.
18. Khoury Sj, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor b, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992; 176: 1355-1365.
19. Sun J-B, Rask C, Olsson T, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci USA 1996; 93: 7196-7201.
20. Merrill JE, Benveniste EN. Cytokines in inflammatory brain lesions: Helpful and harmful. TINS 1996; 19: 331-338.
21. Baker D, Gibjels K, Steinman LS. Cytokines in multiple sclerosis. In: Brennan FM, Feldmann M (eds). The Role of Cytokines in Autoimmunity. R.G. Landes Company, 1996.
22. Metzler B, Wraith DC. Mucosal tolerance in a murine model of experimental autoimmune encephalomyelitis. Ann NY Acad Sci 1996; 778: 228-242.
23. Anderton SM, Burkhart C, Liu GY, Metzler B, Wraith DC. Antigen-specific tolerance induction and the immunotherapy of EAE. Novartis Foundation Symp 1998; 215: 120-131.
24. Al-Sabagh A, Miller A, Sobel RA, Weiner HL. Suppression of PLP-induced EAE in the SJL mouse by oral administration of MBP. Neurology 1992; 42 (Suppl. 3): 346.
25. Ferber IA, Brocke S, Taylor-Edwards C et al. Mice with a disrupted IFN-g gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE)1. J Immunol 1996; 156: 5-7.
26. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor a. Proc Natl Acad Sci USA 1995; 92: 11294-11298.
27. Goverman J, Woods A, Larson L et al. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993; 72: 551-560.
28. Campbell IL, Abraham CR, Masliah E et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA 1993; 90: 10061-10065.
29. Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 1998; 28: 2178-2187.
30. Mendel I, Katz A, Kozak N, Ben-Nun A, Revel M. Interleukin-6 functions in autoimmune encephalomyelitis: A study in gene-targeted mice. Eur J Immunol 1998; 28: 1727-1737.
31. Segal BM, Shevach EM. IL-12 unmasks latent autoimmune disease in resistant mice. J Exp Med 1996; 184: 771-775.
32. Waldner H, Sobel RA, Howard E, Kuchroo VK. Fas-and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J Immunol 1997; 159: 3100-3103.
33. Piddlesden SJ, Storch MK, Hibbs M et al. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 1994; 152: 5477-5484.
34. Broome Powell M, Mitchell D, Lederman J et al. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Intl Immunol 1990; 2: 539-544.
35. Litzenburger T, Fassler R, Bauer J et al. B lymphocytes producing demyelinating autoantibodies: Development and function in gene-targeted transgenic mice. J Exp Med 1998; 188: 169-180.
36. Fenyk-Melody JE, Garrison AE, Brunnert SR, Weidner JR, F. S. Experimental autoimmune encephalomyelitis is exacerbated in mice lacking the NOS2 gene. J Immunol 1998; 160: 2940-2946.
37. Samoilova EB, Horton JL, Chen Y. Acceleration of experimental autoimmune encephalomyelitis in IL-10 deficient mice: Roles of IL-10 in disease progression and recovery. Cell Immunol 1998; 188: 118-124.
38. Liu J, Marino MW, Wong G et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998; 4: 78-83.
39. Steinman L. Some misconceptions about understanding autoimmunity through experiments with knockouts. J Exp Med 1997; 185: 2039-2041.
40. Grewal IS, Foellmer D, Xu J, Hardardottir F. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 1996; 273: 1864-1867.
41. Koh DR, Fung-Leung WP, Ho A et al. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8 -/-mice. Science 1992; 256: 1210-1213.
42. Koh DR, Ho A, Rahemtulla A, Penninger J, Mak TW. Experimental allergic encephalomyelitis (EAE) in mice lacking CD4+ T cells. Eur J Immunol 1994; 24: 2250-2253.
43. Croxford JL, Triantaphyllopoulos K, Podhajcer OL et al. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J Immunol 1998; 160: 5181-5187.
44. Croxford JL, O'Neill JK, Ali RR et al. Local gene therapy with CTLA-4 Ig fusion protein in EAE. Eur J Immunol 1998; 28: 3904-3917.
45. Waisman A, Ruiz PJ, Hirschberg DL et al. Suppressive vaccination with DNA encoding a variable region gene of the T cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat Med 1996; 2: 899-905.
46. Shaw MK, Lorens JB, Dhawan A et al. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J Exp Med 1985; 185: 1711-1714.
47. Chen LZ, Hochwald GM, Huang C et al. Gene therapy in allergic encephalomyelitis using MBP-specific T cells engineered to express latent TGFb1. Proc Natl Acad Sci USA 1998; 95: 12516-12521.
48. Croxford JL, Triantaphyllopoulos K, Neve R et al. Retroviral gene therapy for experimental allergic encephalomyelitis using a novel p75 dimeric TNF receptor. J Immunol 2000; 164: 2776-2781.
49. Harley JB, Moser KL, Gaffney PM, Behrens TW. The genetics of human systemic lupus erythematosus. Curr Op Immunol 1998; 10: 690-696.
50. Brennan P, Hajeer A, Ong KR et al. Allelic markers close to prolactin are associated with HLA-DRB1 susceptibility alleles among women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis & Rheum 1997; 40: 1383-1386.
51. Vaishnaw AK, Toubi E, Ohsako S et al. The spectrum of apoptotic defects and clinical manifestations, including SLE in humans with CD95 (Fas/APO-1) mutations. Arthritis Rheum 1999; 42: 1833-1842.
52. Norsworthy P, Theodoridis E, Botto M et al. Overrepresentation of the Fc gamma type IIA R131/R131 genotype in caucasoid SLE patients with autoantibodies to C1q and glomerulonephritis. Arthritis Rheum 1999; 42: 1828-1832.
53. Morel L, Wakeland EK. Susceptibility to lupus nephritis in the NZB/W model system. Curr Op Immunol 1998; 10: 718-725.
54. Andrews BS, Eisenberg RA, Theofilopoulos AN et al. Spontaneous murine like-lupus syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978; 148: 1198-1215.
55. Duvic M, Steinberg AD, Klassen LW. Effect of the anti-estrogen, Nafoxidine, on NZB/W autoimmune disease. Arthritis & Rheum 1978; 21: 414-417.
56. Roubinian J, Talal N, Siiteri PK, Sadakian JA. Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis & Rheum 1979; 22: 1162-1169.
57. Kotzin BL, Palmer E. The contribution of NZW genes to lupus-like disease in (NZB X NZW) F1 mice. J Exp Med 1987; 165: 1237-1251.
58. Noonan DJ, Kofler R, Singer PA et al. Delineation of a defect in T cell receptor beta genes of NZW mice predisposed to autoimmunity. J Exp Med 1986; 163: 644-653.
59. Steinberg AD, Huston DP, Taurog JD, Cowdery JS, Raveche ES. The cellular and genetic basis of murine lupus. Immunol Rev 1981; 55: 121-154.
60. Perteschuk LP, Moccia LF, Rosen Y et al. Acute pulmonary complications in systemic lupus erythematosus: Immunofluorescence and light microscopic study. Am J Clin Path 1977; 68: 553-557.
61. Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol 1987; 138: 3247-3252.
62. Park CL, Balderas RS, Fieser TM et al. Isotypic profiles and other fine characteristics of immune responses to exogenous thymus-dependent antigens by mice with lupus syndromes. J Immunol 1983; 130: 2161-2167.
63. Datta SK, Manny N, Andrzcjewski C, Andre-Schwartz J, Schwartz RS. Genetic studies of autoimmunity and retrovirus expression in crosses of New Zealand Black mice. I. Xenotropic virus. J Exp Med 1978; 147: 854-871.
64. Gavalchin J, Nicklas JA, Eastcott JW et al. Lupus prone (SWR X NZB) F1 mice produce potentially nephritogenic autoantibodies inherited from the normal SWR1 parent. J Immunol 1985; 134: 885-894.
65. Ando DG, Sercarz EE, Hahn BH. Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model. J Immunol 1987; 138: 3185-3190.
66. Datta SK, Patel H, Berry D. Induction of cataionic shift in IgG anti-DNA autoantibodies. Role of T helper cells with classical and novel phenotype in three models of lupus nephritis. J Exp Med 1987; 165: 1252-1268.
67. Singer PA, Balderas RS, McEvilly RJ, Robardt M, Theofilopoulos AN. Tolerance-related V beta clonal deletion in normal CD4-8 TCR-alpha/beta + and abnormal lpr and gld cell populations. J Exp Med 1989; 170: 1869-1877.
68. Ghatak S, Sainis K, Owens FL, Datta SK. T cell receptor beta and I-A-chain genes of normal SWR mice are linked with the development of lupus nephritis in NZB X SWR crosses. Proc Natl Acad Sci USA 1987; 84: 6850-6853.
69. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-317.
70. Fisher CL, Eisenberg RA, Cohen PL. Quantitation and IgG sub-class distribution of antichromatin autoantibodies in SLE mice. Clin Immunol Immunopathol 1988; 46: 205-213.
71. Theofilopoulos AN, Dixon FJ. Etiopathogenesis of murine systemic lupus erythematosus. Immunol Rev 1981; 55: 179-216.
72. Altman A, Theofilopoulos AN, Weiner R, Katz DH, Dixon FJ. Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J Exp Med 1981; 154: 791-808.
73. Scholz W, Isakov N, Mally MI, Theofilopoulos AN, Altman A. Lpr T cell hyporesponsiveness to mitogens linked to deficient receptor-stimulated phosphoinositide. J Biol Chem 1988; 263: 3626-3631.
74. Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999; 169: 107-121.
75. Shlomchik MJ, Madaio MR, Ni D, Trounstine M, Huszar D. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994; 180: 1295-1306.
76. Peng SL, Madaio MP, Hayday AC, Craft J. Propagation and regulation of systemic autoimmunity by gd T cells. J Immunol 1996; 157: 5689-5698.
77. Jevnikar AM, Grusby MJ, Glimcher LH. Prevention of nephritis in major histocompatibility complex class II deficient MRL-lpr mice. J Exp Med 1994; 179: 1137-1143.
78. Ma J. Autoimmune lpr/lpr mice deficient in CD40 ligand: Spontaneous Ig class switching with dichotomy of autoantibody responses. J Immunol 1996; 157: 417-426.
79. Haas C, Ryffel B, Le Hir M. IFN-g is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J Immunol 1997; 158: 5484-5491.
80. Peng SL, Moslehi J, Craft J. Roles of interferon-g and interleukin-4 in murine lupus. J Clin Invest 1997; 99: 1936-1946.
81. Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998; 199: 265-285.
82. Botto M, Dell'Agnola C, Bygrave AE et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19: 56-59.
83. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154: 1470-1480.
84. Jacob CO, McDevitt HO. Tumor necrosis factor-a in murine autoimmune "lupus" nephritis. Nature 1988; 331: 356-358.
85. Ishida H, Muchamuel T, Sakaguchi S et al. Continuous administration of anti-interleukin 10 antibodies delays the onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994; 179: 305-310.
86. Wang Y, Hu Q, Madri JA et al. Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component 5. Proc Natl Acad Sci USA 1996; 93: 8563-8568.
87. Raz E, Dudler J, Lotz M et al. Modulation of disease activity in murine lupus erythematosus by cytokine gene delivery. Lupus 1995; 4: 286-292.
88. Cunningham MA, Rondeay E, Chen X et al. Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med 2000; 191: 455-461.
89. Schönherr E, Broszat M, Brandan E, Bruckner P, Kresse H. Decorin protein fragment Leu155-Val260 interacts with TGFbeta but does not compete for decorin binding to Type I collagen. Arch Biochem Biophys 1998; 355: 241-248.
90. Todd JA. Genetic control of autoimmunity in type 1 diabetes. Immunol Today 1990; 11: 122-129.
91. Boyton RJ, Lohmann T, Londei M et al. Glutamic acid decarboxylase T lymphocyte responses associated with susceptibility or resistance to type I diabetes: Analysis in disease discordant human twins, nonobese diabetic mice and HLA-DQ transgenic mice. Intl Immunol 1998; 10: 1765-1776.
92. Undlien DE, Friede T, Rammensee HG et al. HLA-Encoded genetic predisposition in IDDM-DR4 subtypes may be associated with different degrees of protection. Diabetes 1997; 46: 143-149.
93. Todd JA, Bell JI, Mcdevitt HO. Hla-dq-beta gene contributes to susceptibility and resistance to insulin-dependent diabetes-mellitus. Nature 1987; 329: 599-604.
94. She JX. Susceptibility to type I diabetes: HLA-DQ and DR revisited. Immunol Today 1996; 17: 323-329.
95. Zhang SL, Cheng H, Fu ZH, Zhong GS, Yan T. Contribution of the absence of aspartic acid at position 57 of the HLA-DQ beta chain to predisposition to insulin-dependent diabetes mellitus in a Southern Chinese population. Chinese Med J 1998; 111: 694-697.
96. Morel PA, Dorman JS, Todd JA, Mcdevitt HO, Trucco M. Aspartic-acid at position 57 of the HLA-DQ beta-chain protects against type-I diabetes - a family study. Proc Natl Acad Sci USA 1988; 85: 8111-8115.
97. Freire M, van Dijk D, Erman A et al. DNA polymorphisms in the ACE gene, serum activity and the risk of nephropathy in IDDM. Nephrol Dial Transplant 1998; 13: 2553-2558.
98. Huang XH, Rantalaiho V, Wirta O et al. Relationship of the angiotensin-converting enzyme gene polymorphism to glucose intolerance, insulin resistance, and hypertension in NIDDM. Hum Genet 1998; 102: 372-378.
99. SchalinJantti C, Nikulaljas P, Huang XD et al. Polymorphism of the glycogen synthase gene in hypertensive and normotensive subjects. Hypertension 1996; 27: 67-71.
100. Shen GQ, Ikegami H, Fujisawa T et al. Asp905Tyr polymorphism of protein phosphatase 1 G subunit gene in hypertension. Hypertension 1997; 30: 236-239.
101. Siffert W, Dusing R. Na+/H+ exchange in hypertension and in diabetes mellitus - facts and hypotheses. Basic Res Cardiol 1996; 91: 179-190.
102. Fogarty DG, Krolewski AS. Genetic susceptibility and the role of hypertension in diabetic nephropathy. Curr Op Nephr Hypertens 1997; 6: 184-191.
103. Colucci F, Bergman ML, PenhaGoncalves C, Cilio CM, Holmberg D. Apoptosis resistance of nonobese diabetic peripheral lymphocytes linked to the Idd5 diabetes susceptibility region. Proc Natl Acad Sci USA 1997; 94: 8670-8674.
104. Elbein SC, Hoffman M, Barrett K et al. Role of the beta(3)-adrenergic receptor locus in obesity and noninsulin-dependent diabetes among members of Caucasian families with a diabetic sibling pair. J Clin Endocrinol Metabol 1996; 81: 4422-4427.
105. Jeyasingam CL, Bryson JM, Caterson ID, Yue DK, Donnelly R. Expression of the beta(3)-adrenoceptor gene polymorphism (Trp64Arg) in obese diabetic and non-diabetic subjects. Clin Exp Pharmacol Physiol 1997; 24: 733-735.
106. Martins TC, Aguas AP. Involvement of c-myc in the resistance of non-obese diabetic mice to glucocorticoid-induced apoptosis. Immunology 1998; 95: 377-382.
107. McDevitt H, Singer S, Tisch R. The role of MHC class II genes in susceptibility and resistance to type I diabetes mellitus in the NOD mouse. Hormone Metabolic Res 1996; 28: 287-288.
108. Miltenberger RJ, Mynatt RL, Wilkinson JE, Woychik RP. The role of the agouti gene in the yellow obese syndrome. J Nutrition 1997; 127: S1902-S1907.
109. Walston J, Lowe A, Silver K et al. The beta(3)-adrenergic receptor in the obesity and diabetes prone rhesus monkey is very similar to human and contains arginine at codon 64. Gene 1997; 188: 207-213.
110. EldarFinkelman H, Schreyer SA, Shinohara MM, LeBoeuf RC, Krebs EG. Increased glycogen synthase kinase-3 activity in diabetes-and obesity-prone C57BL/6J mice. Diabetes 1999; 48: 1662-1666.
111. Falcone M, Lee J, Patstone G, Yeung B, Sarvetnick N. B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J Immunol 1998; 161: 1163-1168.
112. Sarvetnick N, Shizuru J, Liggitt D, Stewart T. Inflammatory destruction of pancreatic beta-cells in gamma-interferon transgenic mice. CSH Symp Quant Biol 1989; 54: 837-842.
113. Falcone M, Sarvetnick N. The effect of local production of cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Clin Immunol 1999; 90: 2-9.
114. Yang XD, Tisch R, Singer SM et al. Effect of tumor-necrosis-factor-alpha on insulin-dependent diabetes-mellitus in nod mice. 1. the early development of autoimmunity and the diabetogenic process. J Exp Med 1994; 180: 995-1004.
115. Gallichan WS, Balasa B, Davies JD, Sarvetnick N. Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. J Immunol 1999; 163: 1696-1703.
116. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996; 184: 1093-1099.
117. King C, Davies J, Mueller R et al. TGF-beta 1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity 1998; 8: 601-613.
118. Kagi D, Ho A, Odermatt B et al. TNF receptor 1-dependent beta cell toxicity as an effector pathway in autoimmune diabetes. J Immunol 1999; 162: 4598-4605.
119. Kagi D, Odermatt B, Seiler P et al. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med 1997; 186: 989-997.
120. Pakala SV, Chivetta M, Kelly CB, Katz JD. In autoimmune diabetes the transition from bening to pernicious insulitis requires an islet cell response to TNFα. J Exp Med 1999; 189: 1053-1062.
121. Ventre J, Doebber T, Wu M et al. Genetic ablation of TNF alpha in mice results in lower triglyceride levels and improved metabolic response to experimental obesity. Diabetes 1997: 46: 327.
122. Ventre J, Doebber T, Wu M et al. Targeted disruption of the tumor necrosis factor-alpha gene: Metabolic consequences in obese and nonobese mice. Diabetes 1997; 46: 1526-1531.
123. Balasa B, Davies JD, Lee J et al. IL-10 impacts autoimmune diabetes via a CD8(+) T cell pathway circumventing the requirement for CD4(+) T and B lymphocytes. J. Immunol 1998; 161: 4420-4427.
124. Horwitz MS, Bradley LM, Harbertson J et al. Diabetes induced by Coxsackie virus: Initiation by bystander damage and not molecular mimicry. Nat Med 1998; 4: 781-785.
125. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158: 2947-2954.
126. Tisch R, Yang XD, Liblau RS, Mcdevitt HO. Administering glutamic-acid decarboxylase to NOD mice prevents diabetes. J Autoimmunity 1994; 7: 845-850.
127. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998; 47: 894-899.
128. Yang XD, Karin N, Tisch R, Steinman L, Mcdevitt HO. Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking 1-selectin and very late antigen-4 adhesion receptors. Proc Natl Acad Sci USA 1993; 90: 10494-10498.
129. Moritani M, Yoshimoto K, Li S et al. Prevention of adoptively transferred diabetes in NOD mice with IL-10-transduced islet-specific Th1 lymphocytes. J Clin Invest 1996; 98: 1851-1859.
130. Lau HT, Yu M, Fontana A, Stoeckert CJ. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273: 109-112.
131. Takeda Y, Gotoh M, Dono K et al. Acceptance of islet allografts transplanted with Fas ligand expressing testicular allografts. Transplantation Proc 1999; 31: 624.
132. Kang SM, Hoffmann A, Le D et al. Immune response and myoblasts that express Fas ligand. Science 1997; 278: 1322-1324.
133. Kon OL, Sivakumar S, Teoh KL, Lok SHL, Long YC. Naked plasmid-mediated gene transfer to skeletal muscle ameliorates diabetes mellitus. J Gene Med 1999; 1: 186-194.
134. Ramiya VK, Maraist M, Arfors KE et al. Reversal of insulin dependent diabetes using islets generated in vitro from pancreatic stem cells. Nat Med 2000; 6: 278-282.
135. Feldmann M, Brennan FM, Abney ER et al. Are imbalances in cytokine function of importance in the pathogenesis of rheumatoid arthritis. In: Davies ME, Dingle JT (eds). Immunopharmacology of Joints and Connective Tissue. Academic Press: London, NY, 1994, pp 119-128.
136. Wordsworth BP, Lanchbury JSS, Sakkas LI et al. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad SCI USA 1989; 86: 10049-10053.
137. Winchester R. The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 1994; 56: 389-150.
138. Lazaro AM, Fernandez Vina MA, McGarry JE et al. HLA-DRB1 homozygosity and heterozygosity with high risk for rheumatoid arthritis. Hum Immunol 1997; 55: 56.
139. Todd JA, Achaorbea H, Bell JI et al. A molecular-basis for MHC class-II - associated autoimmunity. Science 1988; 240: 1003-1009.
140. Mulcahy B, WaldronLynch F, McDermott MF et al. Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am J Hum Gen 1996; 59: 676-683.
141. Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti-tumor necrosis alpha therapy of rheumatoid arthritis. Adv Immunol 1997; 64: 283-350.
142. Moreland LW, Margolies G, Heck Jr LW et al. Recombinant soluble TNF-R (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996; 23: 1849-1855.
143. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF antibodies on synovial cell IL-1 production in rheumatoid arthritis. Lancet 1989; ii: 244.
144. Haralambous S, Plows D, Kollias G. Attenuation of transgenic TNF-triggered arthritis in type I-IL-1 receptor knockout mice. Eur.Cyt Network 1998; 9: 421.
145. Drevlow B, Capezio J, Lovis R et al. Phase I study of recombinant human IL-1 receptor administered intrarticularly in active rheumatoid arthritis. Arthritis Rheum 1993; 36: S39.
146. Moreland LW, Pratt PW, Sanders ME, Koopman WJ. Experience with a chimeric monoclonal anti-CD4 antibody in the treatment of refractory rheumatoid arthritis. Clin Exp Rheumatol 1993; 11 (Suppl. 8): S153-s159.
147. Goldberg D, Morel P, Chantenaud P et al. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J Autoimmun 1991; 4: 617-630.
148. Matsumoto AK, Moreland LW. Results of phase lib rheumatoid arthritis clinical trial using T cell receptor peptides. Arthritis & Rheum 1999; 42: S117.
149. Wooley PH, Lurthra HS, Stuart JM, David CS. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I-region) linkage and antibody correlates. J Exp Med 1981; 154: 688-673.
150. Seki N, Sudo Y, Yoshioka T et al. Type Il-induced murine arthritis. I. Induction and preparation of arthritis require synergy between humoral and cell mediated immunity. J Immunol 1988; 140: 1477-1482.
151. Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human TNF: A predictive genetic model of arthritis. EMBO J 1991; 10: 4025-4031.
152. Butler DM, Malfait AM, Mason LJ et al. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis - Characterization of the cytokine cascade and cellular composition. J Immunol 1997; 159: 2867-2876.
153. Alexopoulou L, Pasparakis M, Kollias G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol 1997; 27: 2588-2592.
154. Wooley PH, Mayton L, Kollias G, Gallo MA. The evolution of arthritis in transgenic mice expressing 3′-modified human tumor necrosis factor alpha transgenes. Arthritis Rheum 1996; 39: 304.
155. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996; 184: 1397-1411.
156. Mauri C, Chu C-QQ, Woodrow D, Mori L, Londei M. Treatment of a newly established transgenic model of chronic arthritis with non-depleting anti-CD4 monoclonal antibody. J Immunol 1997; 159: 5032-5041.
157. Bandara G, Mueller GM, Galea-Lauri J et al. Intraarticular expression of biologically active IL-1 receptor antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 1993; 90: 10764-10768.
158. Vermeire K, Heremans H, VAndeputte M et al. Accelerated collagen-induced arthritis in IFN γ receptor-deficient mice. J Immunol 1997; 158: 5507-5513.
159. Manoury-Schwartz B, Chiocchia G, Bessis N et al. High susceptibility to collagen-induced arthritis in mice lacking IFNγ receptors. J Immunol 1997; 158: 5501-5506.
160. Sasai M, Ohshima S, Nishioka K et al. Delayed onset and reduced severity of collagen-induced arthritis in IL-6 deficient mice. Arthritis Rheum 1999; 42: S123.
161. Chu C-Q, Londei M. Induction of Th2 cytokines and control of collagen-induced arthritis by non-depleting anti-CD4 antibodies. J Immunol 1996; 157: 2685-2689.
162. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994; 91: 2762-2766.
163. Durie FH, Fava RA, Foy TM et al. Prevention of collagen induced arthritis with an antibody to gp39, the ligand to CD40. Science 1993; 261: 1328-1330.
164. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995; 92: 8955-8959.
165. Tarkowski A, Sun J-B, Holmdahl R, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine. Arthritis Rheum 1999; 42: 1628-1634.
166. Plater-Zyberk C, Bonnefoy J-Y. Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo. Nat Med 1995; 1: 781-785.
167. Horsfall A, Butler D, Marinova L et al. Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol 1997; 159: 5687-5696.
168. Jorgensen C, Apparailly F, Canovas F et al. Chondroprotective effect of gene transfer of IL10 in type II collagen induced arthritis. Arthritis Rheum 1997; 40: 1140-1142.
169. Bakker AC, Joosten LAB, Arntz OJ et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human IL-1ra protein in the knee. Arthritis Rheum 1997; 40: 893-900.
170. Joosten LAB, Liberts E, Durez P et al. Role of IL-4 and IL-10 in murine collagen-induced arthritis. Arthritis Rheum 1997; 40: 249-260.
171. Malfait A, Butler D, Presky D et al. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol 1998; 111: 377-383.
172. Butler D, Malfait A, Maini R, Brennan F, Feldmann M. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur J Immunol 1999; 29: 2205-2212.
173. Maksymowych WP, Nation N, Nash P et al. Amelioration of antigen induced arthritis in rabbits treated with a viral serine proteinase inhibitor. J Rheumatol 1996; 23: 878-882.
174. Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP. Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis. Clin Exp Immunol 1997; 110: 45-52.
175. Plater-Zyberk C, Buckton J, Thompson S et al. Amelioration of arthritis in two murine models using antibodies to oncostatin M. Arthritis Rheum 1999; 42: S123.
176. q-IgG3 fusion protein. Arthritis Rheum 1999; 42: S125.
177. Evans CH, Robbins PD, Ghivizzani SC. Clinical trial to assess safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996; 7: 1261-1280.
178. Hung GL, Galea-Lauri J, Mueller GM et al. Suppression of intra-articular responses to IL-1 by transfer of the IL-1 receptor antagonist gene to synovium. Gene Therapy 1994; 1: 64-69.
179. Bessis N, Boissier MC, Caput D, Fradelizi D, Fournier C. Cytokine gene-therapy using IL-4 and IL-13 in murine collagen-induced arthritis. Clin Res 1994; 42: A135.
180. Bessis N, Boissier MC, Ferrara P et al. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur J Immunol 1996; 26: 2399-2403.
181. Bessis N, Chiocchia G, Kollias G et al. Modulation of proinflammatory cytokine production in tumour necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13. Clin Exp Immunol 1998; 111: 391-396.
182. Chernajovsky Y. Systemic gene therapy of arthritis. Drugs of Today 1999; 35: 361-377.
183. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. Amelioration of collagen-induced arthritis and suppression of IFNγ, IL-12 and TNFα production by IFNβ gene therapy. Arthritis Rheum 1999; 42: 90-99.
184. Williams RO, Plater-Zyberk C, Williams DG, Maini RN. Successful transfer of collagen-induced arthritis to SCID mice. Clin Exp Immunol 1992; 88: 455-460.
185. Kasid A, Morecki S, Aebersold P et al. Human gene transfer: Characterization of human TIL as vehicles for retroviral-mediated gene transfer in man. Proc Natl Acad Sci USA 1990; 87: 473-477.
186. Chernajovsky Y, Adams G, Podhajcer O et al. Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble human TNF receptor. Gene Therapy 1995; 2: 731-735.
187. Mageed RA, Adams G, Woodrow D, Podhajcer OL, Chernajovsky Y. Prevention of collagen-induced arthritis by gene transfer of soluble p75TNF receptor. Gene Therapy 1998; 5: 1584-1592.
188. Chernajovsky Y, Adams G, Triantaphyllopoulos K, Ledda MF, Podhajcer OL. Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease in a collagen-induced arthritis model. Gene Therapy 1997; 4: 553-559.
189. Nita I, Ghivizzani SC, Galealauri J et al. Direct gene delivery to synovium - an evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996; 39: 820-828.
190. Makarov SS, Olsen JC, Johnston WN et al. Retrovirus-mediated in vivo gene-transfer to synovium in bacterial-cell wall-induced arthritis in rats. Gene Therapy 1995; 2: 424-428.
191. Roessler BJ, Allen ED, Wilson JM, Hartman JW, Davidson BL. Adenoviral-mediated gene transfer to rabbit synovium in vivo. J Clin Invest 1993; 92: 1085-1092.
192. Makarov SS, Baldwin AS. Local suppression of NF-kappa-B inhibits experimental arthritis in rats. Arthritis Rheum 1996; 39: S563.
193. Bondeson J, Foxwell B, Brennan F, Feldmann M. Defining therapeutic targets by using adenovirus: Blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci USA 1999; 96: 5668-5673.
194. Ghivizzani SC, Kang R, Hatton C et al. In vivo delivery of genes encoding soluble receptors for IL-1 and TNF-alpha results in a synergistic therapeutic effect in antigen-induced arthritis in the rabbit knee. Arthritis Rheum 1996; 39: S308.
195. Zhang H, Yang Y, Horton JL et al. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest 1997; 100: 1951-1957.
196. Oligino T, Ghivizzani SC, Wolfe D et al. Intraarticular delivery of a herpes simplex virus IL-1ra gene vector reduces inflammation in a rabbit model of arthritis. Gene Therapy 1999; 6: 1713-1720.
197. Song XY, Gu M, Jin, Klinman M, Wahl SM. Plasmid DNA encoding TGFβ1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J Clin Invest 1998; 101: 1-7.
198. Rosloniec EF, Brand DD, Whittington KB, Stuart JM, Ciubotaru M. Vaccination with a recombinant v-alpha domain of a TCR prevents the development of collagen-induced arthritis. J Immunol 1995; 155: 4504-4511.
199. Gazit D, Turgeman G, Kelley P et al. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: A novel cell-mediated gene therapy. J Gene Med 1999; 1: 121-133.
200. Annenkov A, Moyes S, Eshhar Z, Mageed R, Chernajovsky Y. Loss of original specificity in T cells redirected to collagen by transduction with a chimeric receptor containing scFv of anti-collagen antibody and Fc∈R1 signaling γ subunit. J Immunol 1998; 161: 6604-6613.
201. Annenkov A, Chernajovsky Y. Engineering mouse T lymphocytes specific to type II collagen by transduction with a chimeric receptor consisting of a scFv and TCRζ. Gene Therapy 2000 (in press).
202. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551.
203. Gossen M, Freundlieb S, Bender G et al. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-1769.
204. Bohl D, Naffakh N, Heard J-M. Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nat Med 1997; 3: 299-305.
205. Aebischer P, Schluep M, Déglon N et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotropic lateral sclerosis patients. Nat Med 1996; 2: 696-699.
206. Wicks I, Cooley H, Szer J. Autologous hemopoietic stem cell transplantation: A possible cure for rheumatoid arthritis? Arthritis Rheum 1997; 40: 1005-1011.
207. Burt RK, Burns WH, Miller SD. Bone marrow transplantation for multiple sclerosis: Returning to Pandora's box. Immunol Today 1997; 12: 559-561.
208. Van Bekkum DW, Bohre EP, Houben PF, Knaan-Shannzer S. Regression of adjuvant-induced arthritis in rats following bone marrow transplantation. Proc Natl Acad Sci USA 1989; 86: 10090-10094.
209. Knaan-Shanzer S, Houben P, Kinwell-Bohre EP, Van Bekkum DW. Remission induction of adjuvant arthritis in rats by total body irradiation and autologous bone marrow transplantation. Bone Marrow Transpl 1991; 8: 333-338.
210. Ikehara S, Kawamura M, Takao F et al. Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells. Proc Natl Acad Sci USA 1990; 87: 8341-8344.
211. Ida T, Yasumizu R, Ohnishi Y et al. Analyses of development of insulitogenic T lymphocytes in NOD mice by transplantation of bone marrow, thymus, and pancreas. Transplantation 1990; 49: 976-982.